Bao Pharma shares jumped 105.3% in in Hong Kong grey market.
Founded in 2019, Bao Pharma focuses on four key therapeutic areas, including large-volume subcutaneous drug delivery systems, antibody-mediated autoimmune disease therapies, assisted reproduction and recombinant biologics.
The company recorded revenue of 41.99 million yuan ($5.94 million) in the first half of this year, up 27.2 times year-on-year from 1.49 million yuan in the same period last year. During the same period, its loss widened 9.4% year-on-year to 180 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments